CJC-1295 (with DAC)

CJC-1295 (with DAC) is a synthetic tetrasubstituted analog of growth hormone-releasing hormone engineered with a Drug Affinity Complex. The DAC moiety forms a covalent bond with circulating serum albumin, extending the peptide half-life from minutes to multiple days in experimental systems. This property positions the compound as a laboratory tool for examining prolonged GHRH-receptor occupancy. It is supplied exclusively for in-vitro and controlled laboratory research.

In model systems the peptide binds GHRH receptors expressed on somatotroph cells, activating Gs-coupled signaling that elevates cyclic AMP and promotes growth-hormone gene transcription and secretion. Concurrent albumin binding via the DAC group maintains receptor stimulation over extended intervals, producing a continuous rather than episodic GH output. Downstream, the sustained GH elevation drives measurable increases in insulin-like growth factor-1 in the same experimental preparations. Researchers exploit this profile to dissect tonic versus pulsatile endocrine signaling.

Investigators employ CJC-1295 (with DAC) to map the consequences of uninterrupted GHRH-receptor activation on baseline GH and IGF-1 trajectories across multi-day observation windows. Comparative studies contrast this continuous “GH bleed” pattern with the discrete pulses generated by short-acting GHRH fragments or ghrelin mimetics. Additional work examines receptor desensitization kinetics, second-messenger dynamics, and transcriptional feedback loops under prolonged ligand exposure in cell-culture and isolated-tissue models.

Laboratory data confirm that albumin conjugation markedly lengthens circulating residence time relative to unmodified GHRH analogs. Sustained receptor engagement elevates trough GH concentrations and secondary IGF-1 levels for days rather than hours in preclinical preparations. Parallel experiments demonstrate that continuous stimulation produces distinct gene-expression signatures compared with intermittent secretagogue challenge. These observations establish the compound as a reference agent for duration-dependent endocrine pathway analysis.

CJC-1295 (with DAC) is intended solely for in-vitro assays and non-clinical laboratory investigation. Standard peptide-handling practices apply: protect from repeated freeze-thaw cycles, reconstitute in appropriate research-grade diluents, and store lyophilized material under desiccated, low-temperature conditions. All experimental designs must remain confined to controlled research environments; the material is not for human or animal consumption.